Blood Clots - redOrbit

News - Blood Clots

FDA Advisory Committee Recommends Against Approval of Oral Anticoagulant XARELTO® to Reduce the Risk of Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome

2012-05-23 10:26:08

Anti-Xa Therapy to Lower cardiovascular events in Addition to aspirin with/without thienopyridine therapy in Subjects with Acute Coronary S

New Study Links Blood Clot Risk to NuvaRing

2012-05-17 23:01:49

According to the study published on May 10th 2012 in the British Medical Journal, non-oral contraceptives, including NuvaRing, have a higher risk of blood clots than combined oral contraceptives

Janssen Research & Development Submits Supplemental New Drug Application to U.S. FDA for XARELTO® (rivaroxaban) to Reduce the Risk of Stent Thrombosis in Patients with Acute Coronary Syndrome

2012-05-09 02:27:35

Anti-Xa Therapy to Lower cardiovascular events in Addition to aspirin with/without thienopyridine therapy in Subjects with Acute Coronary S

Yaz and Yasmin Litigants Offered Settlement Funding by RD Legal Funding

2012-05-02 10:26:21

CRESSKILL, N.J., May 2, 2012 /PRNewswire/ -- Deadlines for lawsuits over side effects of the birth control drugs Yaz and Yasmin have been moved back another 90 days, the third time deadlines

Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism

2012-05-02 02:28:13

RARITAN, N.J., May 2, 2012 /PRNewswire/ -- Janssen Research & Development, LLC, (Janssen), announced today that it has submitted supplemental New Drug Applications (sNDAs) to the U.S.

More News (183 articles) »